Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1), which is another pharmaceutical approach to treat T2DM by enhancing GLP-1 function (Rabiei et al., 2021). Here, GCG is linked to type 2 diabetes mellitus.